Back to search

Peptide record

TPDB41602

LJP-2 Anticancer standard
6 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41602
LJP-2
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 6-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
LWEHSH
Physicochemical Analysis
C37H49N11O10
ARNDCQGIKMFPTYV
H
807.86
6.01
2
1
2
-1
1.66
-1.300
65.00
Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min
5500
680.81
1
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
1
E
0
Q
0
G
2
H
0
I
1
L
0
K
0
M
0
F
0
P
1
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 1 Q: 0 G: 0 H: 2 I: 0 L: 1 K: 0 M: 0 F: 0 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
6
C37H49N11O10
807.86
6.01
-1
1.66
-1.300
Free
L
Linear
Free
Anticancer
Laminaria japonica
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 2.25 ± 0.22 mM
Anticancer
2.25

Target

Liver Cancer
Huh-7
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 1.71 ± 0.13 mM
Anticancer
1.71

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 3 Activity

Activity

IC50
IC50 = 0.62 ± 0.05 mM
Anticancer
0.62

Target

Liver Cancer
H-22
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022